SpyGlass Pharma’s Remarkable, Positive 36-Month IOL Results
SpyGlass Pharma reported a 37% mean intraocular pressure reduction at 36 months in its first-in-human study of the bimatoprost...
eClinical Tech News
NEK7 Degrader MRT-8102 Shows Promise in Preclinical Data
Preclinical data presented at AHA 2025 show MRT-8102, an oral NEK7-directed molecular glue degrader, selectively degrades NEK7, suppresses NLRP3...
Telitacicept Hits Endpoint in Phase 3 IgA Nephropathy Trial
Telitacicept reduced the 24-hour urine protein-to-creatinine ratio by 58.9% at Week 39, compared with an 8.8% reduction on placebo...
Bioversys’ Important BV100 Phase 2b Trial Gets Wellcome Fund
BV100 will advance to an open-label, randomized Phase 2b trial for carbapenem-resistant Acinetobacter baumannii infections, with 90 evaluable patients...
Medera Presents Promising New Heart Failure Gene Therapy Data
Interim results from Medera’s MUSIC-HFpEF Phase 1/2a study reported no gene therapy–related serious adverse events among 10 treated patients,...
Pacira Finishes Enrollment for Phase 2 Knee Drug Study
Pacira has completed enrollment in Part A of its Phase 2 ASCEND trial of PCRX-201, a locally administered IL‑1Ra...
Coherus Presents Biomarker Data for anti-CCR8 Antibody CHS-114
CHS-114, a cytolytic anti-CCR8 antibody, reduced intratumoral CCR8+ Tregs by 74% and total FOXP3+ Tregs by 43%, while increasing...
ProKidney Presents Full Phase 2 Rilparencel Trial Results
In a Phase 2 open-label study of patients with advanced CKD and diabetes, bilateral renal injections of rilparencel improved...
Atacicept Delivers Remarkable Phase 3 Data for IgA Nephropathy
At 36 weeks, atacicept delivered a 46% reduction from baseline in 24-hour urine protein-to-creatinine ratio and a 42% reduction...
Chemomab Announces New Nebokitug PSC Data at Liver Meeting
Nebokitug maintained favorable safety and sustained biomarker improvement through 48 weeks in the Phase 2 SPRING open-label extension in...